Fulgent Genetics (NASDAQ:FLGT) released its fourth-quarter and full-year 2025 results on February 27, 2026, reporting annual revenue growth of 14% to $322.7 million, while fourth-quarter revenue increased 9% year over year to $83.3 million. The company recorded GAAP net losses of $23.4 million for the quarter and $60.5 million for the full year, but generated non-GAAP profit of $5.2 million in Q4 and $13.2 million for 2025, supported by improving margins, expansion of AI- and digital pathology-driven laboratory services, and continued advancement of its oncology pipeline. During the year, FID-007 progressed through Phase 2 trials and FID-022 continued development in Phase 1.
Management emphasized operational streamlining efforts, efficiency gains, and a strong liquidity position at year-end, with $705.5 million in cash and investments, excluding an anticipated tax refund. For 2026, the company expects revenue of approximately $350 million and forecasts a non-GAAP loss per share. Fulgent noted that insourcing activity by its largest customer will weigh on performance in the near term, although this impact could be partly or fully offset later in the year through contributions from the Bako and StrataDx acquisitions as well as ongoing strategic investments. The company said it remains confident in its longer-term growth outlook.
More about Fulgent Genetics
Fulgent Genetics, Inc. is a precision medicine company combining advanced technology with laboratory services and therapeutic development. Its laboratory segment provides diagnostic testing and physician-guided interpretation services, while its therapeutics division focuses on developing nanoencapsulated, targeted cancer treatments designed to enhance safety and effectiveness. The company is evolving from a diagnostics-focused organization toward a fully integrated precision medicine platform.